Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, July 2, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $300.62 to $7,318,309.60.

Highlighted Stocks Traded by Insiders:

Blackstone Mortgage (BXMT) - FREE Research Report

Marone Anthony F. JR, who is Principal Accounting Officer at Blackstone Mortgage, sold 179 shares at $27.69 on July 2, 2015. Following this transaction, the Principal Accounting Officer owned 11,288 shares meaning that the stake was reduced by 1.56% with the 179-share transaction.

Quinlan Paul D, who is Chief Financial Officer at Blackstone Mortgage, sold 245 shares at $27.69 on July 2, 2015. Following this transaction, the Chief Financial Officer owned 15,383 shares meaning that the stake was reduced by 1.57% with the 245-share transaction.

Armer Douglas N., who is Treasurer, Managing Director at Blackstone Mortgage, sold 545 shares at $27.69 on July 2, 2015. Following this transaction, the Treasurer, Managing Director owned 30,313 shares meaning that the stake was reduced by 1.77% with the 545-share transaction.

The shares most recently traded at $28.43, up $0.74, or 2.6% since the insider transaction. Historical insider transactions for Blackstone Mortgage go as follows:

  • 4-Week # shares bought: 90,164
  • 4-Week # shares sold: 1,276
  • 12-Week # shares bought: 90,164
  • 12-Week # shares sold: 1,276
  • 24-Week # shares bought: 90,164
  • 24-Week # shares sold: 1,276

The average volume for Blackstone Mortgage has been 1.2 million shares per day over the past 30 days. Blackstone Mortgage has a market cap of $2.3 billion and is part of the financial sector and real estate industry. Shares are down 2.47% year-to-date as of the close of trading on Wednesday.

Blackstone Mortgage Trust, Inc., a real estate finance company, originates and purchases senior loans collateralized by properties in North America and Europe. It operates through two segments, Loan Origination and CT Legacy Portfolio. The stock currently has a dividend yield of 7.48%. The company has a P/E ratio of 13.1. Currently, there are 7 analysts who rate Blackstone Mortgage a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Recommends

Exclusive Offer: Get the latest Stock Analysis on BXMT - FREE

TheStreet Quant Ratings

rates Blackstone Mortgage as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Blackstone Mortgage Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alkermes (ALKS) - FREE Research Report

Breyer Robert A, who is Director at Alkermes, sold 2,000 shares at $64.90 on July 2, 2015. Following this transaction, the Director owned 47,156 shares meaning that the stake was reduced by 4.07% with the 2,000-share transaction.

The shares most recently traded at $63.07, down $1.83, or 2.9% since the insider transaction. Historical insider transactions for Alkermes go as follows:

  • 4-Week # shares bought: 1,600
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 1,600
  • 12-Week # shares sold: 4,000
  • 24-Week # shares bought: 1,600
  • 24-Week # shares sold: 4,000

The average volume for Alkermes has been 1.1 million shares per day over the past 30 days. Alkermes has a market cap of $9.6 billion and is part of the health care sector and drugs industry. Shares are up 10.6% year-to-date as of the close of trading on Wednesday.

Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. Currently, there are 5 analysts who rate Alkermes a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALKS - FREE

TheStreet Quant Ratings

rates Alkermes as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity. Get the full

Alkermes Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

First Merchants (FRME) - FREE Research Report

Lorentson Jeffrey B, who is Chief Risk Officer at First Merchants, bought 15 shares at $20.04 on July 2, 2015. Following this transaction, the Chief Risk Officer owned 13,175 shares meaning that the stake was boosted by 0.11% with the 15-share transaction.

Stewart Michael J, who is Chief Banking Officer at First Merchants, bought 45 shares at $20.04 on July 2, 2015. Following this transaction, the Chief Banking Officer owned 39,045 shares meaning that the stake was boosted by 0.12% with the 45-share transaction.

The shares most recently traded at $24.86, up $4.82, or 19.38% since the insider transaction. Historical insider transactions for First Merchants go as follows:

  • 4-Week # shares bought: 93
  • 4-Week # shares sold: 1,600
  • 12-Week # shares bought: 188
  • 12-Week # shares sold: 1,600
  • 24-Week # shares bought: 546
  • 24-Week # shares sold: 4,600

The average volume for First Merchants has been 91,700 shares per day over the past 30 days. First Merchants has a market cap of $933.2 million and is part of the financial sector and banking industry. Shares are up 10.11% year-to-date as of the close of trading on Wednesday.

First Merchants Corporation operates as the financial holding company for First Merchants Bank, National Association that provides community banking services. The stock currently has a dividend yield of 1.78%. The company has a P/E ratio of 14.5. Currently, there is 1 analyst who rates First Merchants a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRME - FREE

TheStreet Quant Ratings

rates First Merchants as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

First Merchants Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.